AWM
VNDA icon

Avior Wealth Management’s Vanda Pharmaceuticals VNDA Stock Holding History

Avior Wealth Management’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-10
Closed -$41 – 3697
2024
Q1 		$41 Buy
+10
New +$40 ﹤0.01% 3529

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Avior Wealth Management's VNDA Position: Q2 2024 in Review

Avior Wealth Management sold out of Vanda Pharmaceuticals (VNDA) in Q2 2024, closing a stake of 10 shares — an estimated $41 sold.

Avior Wealth Management first reported a position in VNDA in Q1 2024 and held it in 1 quarter. The position peaked at $41 in Q1 2024. 148 funds tracked by Wall St. Rank hold VNDA as of Q2 2024.

  • Avior Wealth Management reported no remaining Vanda Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 10 Vanda Pharmaceuticals shares in Q2 2024, an estimated $41.
  • Avior Wealth Management first reported a position in Vanda Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Vanda Pharmaceuticals position peaked at $41 in Q1 2024.
  • 148 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.